玛莱克琳生物技术公司Moleculin Biotech, Inc.（MBRX） 2025年第一季度财报「NASDAQ」（英文版）（24页）.pdf

1、 Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES E

2、XCHANGE ACT OF 1934For the transition period from to Commission File Number:001-37758MOLECULIN BIOTECH,INC.(Exact name of registrant as specified in its charter)Delaware 2834 47-4671997(State or Other Jurisdiction ofIncorporation or Organization)(Primary Standard IndustrialClassification Code Number

3、)(IRS EmployerIdentification Number)5300 Memorial Drive,Suite 950 Houston,TX77007(Address of principal executive offices)(Zip Code)713-300-5160(Registrants telephone number,including area code)Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or

4、 15(d)of the Securities Exchange Act of 1934 during the preceding 12months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes X No Indicate by check mark whether the registrant has submitted el

5、ectronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T during thepreceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes X No Indicate by check mark whether the registrant is a large accelerated fil

6、er,an accelerated filer,a non-accelerated filer,a smaller reporting company or an emerging growth company.See definitions of large accelerated filer,”accelerated filer,”smaller reporting company,”and emerging growth company”in Rule 12b-2 of the Exchange Act.:Large accelerated filer Smaller reporting